Given the potential importance of epithelial plasticity (EP) to cancer metastasis, we sought to investigate biomarkers related to EP in men with localized prostate cancer (PC) for the association with time to PSA recurrence and other clinical outcomes after surgery.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Men with localized PC treated with radical prostatectomy at the Durham VA Medical Center and whose prostatectomy tissues were included in a tissue microarray (TMA) linked to long-term outcomes. We performed immunohistochemical studies using validated antibodies against E-cadherin and Ki-67 and mesenchymal biomarkers including N-cadherin, vimentin, SNAIL, ZEB1 and TWIST. Association studies were conducted for each biomarker with baseline clinical/pathologic characteristics an risk of PSA recurrence over time.
Two hundred and five men contributed TMA tissue and had long-term follow-up (median 11 years). Forty-three percent had PSA recurrence; three died of PC. The majority had high E-cadherin expression (86%); 14% had low/absent E-cadherin expression. N-cadherin was rarely expressed (<4%) and we were unable to identify an E-to-N-cadherin switch as independently prognostic. No associations with clinical risk group, PSA recurrence or Gleason sum were noted for SNAIL, ZEB1, vimentin or TWIST, despite heterogeneous expression between patients. We observed an association of higher Ki-67 expression with Gleason sum (P=0. 043), National Comprehensive Cancer Network risk (P=0. 013) and PSA recurrence (hazard ratio 1. 07, P=0. 016).
The expression of EP biomarkers in this cohort of men with a low risk of PC-specific mortality was not associated with aggressive features or PSA relapse after surgery. Prostate Cancer and Prostatic Diseases advance online publication, 13 October 2015; doi:10. 1038/pcan. 2015. 46.
Prostate cancer and prostatic diseases. 2015 Oct 13 [Epub ahead of print]
A J Armstrong, P Healy, S Halabi, R Vollmer, A Lark, G Kemeny, K Ware, S J Freedland
Department of Medicine/Division of Medical Oncology, Durham, NC, USA. , Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. , Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. , Department of Pathology, Duke University and the Durham VA Medical Center, Durham, NC, USA. , Department of Pathology, Duke University and the Durham VA Medical Center, Durham, NC, USA. , Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. , Department of Molecular Genetics and Microbiology, Durham, NC, USA. , Department of Surgery/Division of Urology, Duke University and the Durham VA Medical Center, now at Cedars-Sinai Medical Center, Durham, NC, USA.